<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387215</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-214-104</org_study_id>
    <nct_id>NCT03387215</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study
      in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiogram with Doppler imaging and hemodynamic monitoring</measure>
    <time_frame>2 hours</time_frame>
    <description>Cardiac systolic and diastolic function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram (ECG)</measure>
    <time_frame>2 hours</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic monitoring</measure>
    <time_frame>5-6 hours</time_frame>
    <description>Cardiac systolic and diastolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-emergent adverse events</measure>
    <time_frame>5 days</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma and urine levels of cAMP and cGMP as Exploratory biomarkers</measure>
    <time_frame>2 hours</time_frame>
    <description>Pharmacodynamics</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>10 mg ITI-214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg ITI-214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mg - 150 mg ITI-214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITI-214</intervention_name>
    <description>Oral</description>
    <arm_group_label>10 mg ITI-214</arm_group_label>
    <arm_group_label>30 mg ITI-214</arm_group_label>
    <arm_group_label>75 mg - 150 mg ITI-214</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA class II-III heart failure

          -  Ejection fraction equal to or below 35%

          -  On stable heart failure drug treatment

        Exclusion Criteria:

          -  Considered medically inappropriate for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kimberly Vanover, PhD</last_name>
    <phone>646-440-9333</phone>
    <email>itciclinicaltrials@intracellulartherapies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nisha Gilotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

